Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antipsychotic Drugs: Typical and Atypical Agents

Antipsychotic Drugs: Typical and Atypical Agents

Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...

Psychosis and Antipsychotic Drugs: Overview

Psychosis and Antipsychotic Drugs: Overview

The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic symptoms in all...

Antidepressant Drugs: MAOIs and Other Agents

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...

Antipsychotic Drugs: Therapeutic Uses and Side Effects

Antipsychotic Drugs: Therapeutic Uses and Side Effects

Antipsychotic drugs primarily block dopamine and serotonin receptors and cholinergic, adrenergic, and histaminergic receptors, thereby reducing hallucinations and delusions in conditions like schizophrenia. However, they can trigger unwanted extrapyramidal effects such as dystonias, Parkinson-like symptoms, and tardive dyskinesia.
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...

Drug Dosing: Obese Patients

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...

Psychosis: Goals of Pharmacotherapy

Psychosis: Goals of Pharmacotherapy

Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Assessment of Negative Symptoms in Clinical Trials of Acute Schizophrenia: Test of a Novel Enrichment Strategy.

Schizophrenia bulletin open·2024

Same author

Effects of ulotaront on brain circuits of reward, working memory, and emotion processing in healthy volunteers with high or low schizotypy.

Schizophrenia (Heidelberg, Germany)·2023

Same author

The Effect of Lurasidone on Anxiety Symptoms in Patients With Bipolar Depression: A Post Hoc Analysis.

The Journal of clinical psychiatry·2023

Same author

A multicenter, double-blind, placebo-controlled, randomized, Phase 1b crossover trial comparing two doses of ulotaront with placebo in the treatment of narcolepsy-cataplexy.

Sleep medicine·2023

Same author

Sleep Disturbance, Irritability, and Response to Lurasidone Treatment in Children and Adolescents with Bipolar Depression.

Current neuropharmacology·2022

Same author

Safety and effectiveness of ulotaront (SEP-363856) in schizophrenia: results of a 6-month, open-label extension study.

NPJ schizophrenia·2021

Same journal

Quality evaluation of randomized controlled trials of antipsychotic drugs for schizophrenia published in Chinese journals.

Schizophrenia research·2026

Same journal

FL-SDGIN: A federated graph learning approach for schizophrenia diagnosis integrating static and dynamic brain functional networks.

Schizophrenia research·2026

Same journal

Weight loss and gut microbial changes associated with semaglutide among people living with schizophrenia receiving clozapine or olanzapine: An open-label 24-week semaglutide intervention and 76-week trial.

Schizophrenia research·2026

Same journal

Converting negative symptom dimension scores across SANS and PANSS.

Schizophrenia research·2026

Same journal

Inflammation-associated alterations in mGluR transcript expression in the human nucleus accumbens independent of schizophrenia diagnosis.

Schizophrenia research·2026

Same journal

One social interaction after another: Dynamic modeling of social experience in schizophrenia.

Schizophrenia research·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 24, 2026

Self-Administration of Drugs in Mouse Models of Feeding and Obesity

Self-Administration of Drugs in Mouse Models of Feeding and Obesity

Published on: June 8, 2021

Weight effects associated with antipsychotics: a comprehensive database analysis.

Bruce Parsons¹, David B Allison, Antony Loebel

¹Pfizer Inc., 235 E. 42nd Street, New York, NY 10017-5755, USA. bruce.parsons.@pfizer.com

Schizophrenia Research

|March 27, 2009

Summary

This summary is machine-generated.

Weight gain varies significantly among atypical antipsychotics. Olanzapine and risperidone showed higher incidence of weight gain compared to placebo, while ziprasidone did not differ significantly, offering crucial insights for treatment selection.

More Related Videos

Multidisciplinary Approach to Obesity Management: A Case Report

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

Related Experiment Videos

Last Updated: Jun 24, 2026

Self-Administration of Drugs in Mouse Models of Feeding and Obesity

Self-Administration of Drugs in Mouse Models of Feeding and Obesity

Published on: June 8, 2021

Multidisciplinary Approach to Obesity Management: A Case Report

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

Area of Science:

Psychiatry
Pharmacology
Clinical Research

Background:

Atypical antipsychotic-induced weight gain data are limited by methodological factors.
This study evaluates short-term and long-term weight effects of common atypical antipsychotics.

Purpose of the Study:

To compare weight changes associated with amisulpride, haloperidol, olanzapine, risperidone, and ziprasidone against placebo.
To assess weight gain incidence and patterns across different treatment durations.

Main Methods:

Analysis of an integrated clinical trial database from 21 randomized, placebo-controlled studies.
Fixed- and random-effects models used to estimate weight change and gain percentage.
Defined treatment exposure windows for short-term (4-12 weeks) and long-term (6 months, 1 year) analyses.

Main Results:

Long-term (1-year) ziprasidone (17%) and haloperidol (41%) weight gain incidence did not significantly differ from placebo (13%).
Olanzapine (57%) and risperidone (39%) showed significantly higher weight gain incidence versus placebo.
Differential weight change patterns observed, with median monthly changes for haloperidol, ziprasidone, olanzapine, and risperidone differing from placebo.

Conclusions:

Confirms significant differences in long-term weight effects among atypical antipsychotics.
Findings align with previous meta-analyses and large-scale schizophrenia studies.
Highlights the importance of considering differential weight gain profiles in clinical practice.